- Home
- MVIS vs RGNX Comparison
MVIS vs RGNX Comparison
Compare MVIS & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVIS
- RGNX
- Stock Information
- Founded
- MVIS 1993
- RGNX 2008
- Country
- MVIS United States
- RGNX United States
- Employees
- MVIS N/A
- RGNX N/A
- Industry
- MVIS Industrial Machinery/Components
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MVIS Technology
- RGNX Health Care
- Exchange
- MVIS Nasdaq
- RGNX Nasdaq
- Market Cap
- MVIS 403.3M
- RGNX 451.1M
- IPO Year
- MVIS 1996
- RGNX 2015
- Fundamental
- Price
- MVIS $1.43
- RGNX $10.69
- Analyst Decision
- MVIS Strong Buy
- RGNX Strong Buy
- Analyst Count
- MVIS 3
- RGNX 8
- Target Price
- MVIS $2.50
- RGNX $28.50
- AVG Volume (30 Days)
- MVIS 5.7M
- RGNX 501.4K
- Earning Date
- MVIS 11-06-2025
- RGNX 11-05-2025
- Dividend Yield
- MVIS N/A
- RGNX N/A
- EPS Growth
- MVIS N/A
- RGNX N/A
- EPS
- MVIS N/A
- RGNX N/A
- Revenue
- MVIS $2,584,000.00
- RGNX $155,782,000.00
- Revenue This Year
- MVIS N/A
- RGNX $203.27
- Revenue Next Year
- MVIS $857.46
- RGNX $0.58
- P/E Ratio
- MVIS N/A
- RGNX N/A
- Revenue Growth
- MVIS N/A
- RGNX 74.95
- 52 Week Low
- MVIS $0.80
- RGNX $5.04
- 52 Week High
- MVIS $1.95
- RGNX $12.22
- Technical
- Relative Strength Index (RSI)
- MVIS 71.37
- RGNX 65.40
- Support Level
- MVIS $1.23
- RGNX $9.55
- Resistance Level
- MVIS $1.48
- RGNX $11.00
- Average True Range (ATR)
- MVIS 0.09
- RGNX 0.50
- MACD
- MVIS 0.02
- RGNX 0.12
- Stochastic Oscillator
- MVIS 85.71
- RGNX 86.73
About MVIS MicroVision Inc.
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.